SCHEDULE: Soleus Funds Report 5.2% Stake in Prelude Therapeutics

Soleus Capital Management L.P. and affiliated entities report beneficial ownership of 5.2% of Prelude Therapeutics Inc. common stock as of April 21, 2026.

Summary

• Soleus Capital Management L.P. and its affiliated entities have collectively acquired a beneficial ownership stake of 5.2% in Prelude Therapeutics Inc.
• This stake amounts to 3,378,378 shares of common stock.
• The filing indicates that the shares are held through various Soleus entities, including Soleus Private Equity Fund III, L.P., Soleus Capital Master Fund, L.P., and managed by Soleus Capital Management, L.P.
• Guy Levy is identified as the managing member for the general partners and managers of these entities.
• The total number of outstanding shares of Prelude Therapeutics Inc. common stock as of April 27, 2026, was 64,914,770.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes and does not provide operational or financial performance data for Prelude Therapeutics itself.

Positives

• Significant investment by Soleus Capital Management and its affiliates, indicating confidence in Prelude Therapeutics.
• The reporting entities collectively hold a substantial 5.2% stake, which could signal potential for future strategic involvement or influence.

Negatives

• The filing does not contain financial performance data, strategic updates, or risk factors for Prelude Therapeutics itself, as it is a Schedule 13G filing focused on beneficial ownership.
• The disclaimer of beneficial ownership by Guy Levy and several entities for purposes other than Section 13(d) obligations may create ambiguity regarding ultimate control or intent.

Risks

• Potential for increased market volatility if the reporting entities decide to significantly alter their stake.
• The disclaimer of beneficial ownership by several parties could obscure the true decision-making authority or intent behind the investment.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance from Prelude Therapeutics Inc. regarding its financial performance or business operations.

Management Comments

• Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
• Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
• Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing indicates a significant investment by a known investment management firm in Prelude Therapeutics. Such filings often precede or coincide with shifts in a company's shareholder base and can be an indicator of institutional interest or potential strategic changes.

Stakeholder Impact

• Shareholders: The increased institutional ownership may influence future corporate decisions and potentially impact share price dynamics.
• Management: The reporting entities' stake could lead to increased engagement with Prelude Therapeutics' management regarding strategy and governance.

Next Steps

• Monitor future filings from Soleus Capital Management and its affiliates for any changes in their beneficial ownership of Prelude Therapeutics.
• Observe Prelude Therapeutics' future corporate actions and disclosures for any potential impact from this significant shareholder.

Key Dates

Keywords

Prelude Therapeutics, Schedule 13G, Beneficial Ownership, Soleus Capital Management, Investment, SEC Filing, Equity Stake